#Somatic Genome Editing

[autodidacticpolymath-blog]

A Policy arm @ Cambridge had VERY interesting use of "confidential" patient data for Genomic & Medical Research during and post COVID.

20 15 Pathogen genomics into practice Data sharing to support UK clinical genetics and genomics services Genetic screening programmes: an international review of assessment criteria 2017 Personalised prevention in breast cancer – the policy landscape Developing effective ctDNA testing services for lung cancer Linking and sharing routine health data for research Variant classification and…

[darkmaga-returns]

If you stand on a river bank and wait for failed gene therapies to float by… you will be flooded! Admission of failure from the pharma propaganda outlets, on the other hand, is a rare event. This washed up in my inbox recently:

“Exclusive: CRISPR delivery startup, based on UC Berkeley and UCSF science, shuts down.”

and, an even more damning long article questioning the future of the entire CRISPR segment:

“Will CRISPR matter?”

I am posting some excerpts here, with my commentary.

First, what is CRISPR? It is a Nobel Prize winning (of course) “gene editing” technology, long hyped-up as a revolution in health and medicine, and advertised as absolutely 100% functioning and real method for making genetically modified organisms (GMOs) of animals, plants and even humans. Wikipedia says:

The technique is considered highly significant in biotechnology and medicine as it enables editing genomes in vivo and is precise, cost-effective, and efficient. It can be used in the creation of new medicines, agricultural products, and genetically modified organisms, or as a means of controlling pathogens and pests. It also offers potential in the treatment of inherited genetic diseases as well as diseases arising from somatic mutations such as cancer. However, its use in human germline genetic modification is highly controversial. The development of this technique earned Jennifer Doudna and Emmanuelle Charpentier the Nobel Prize in Chemistry in 2020.

They even put someone in China in jail for reportedly making GMO designer babies with this technique. So, it must work, right? If you can make an entire designer baby, or cows without horns, then you should be able to fix someone’s vision with this method, i.e. fix just one feature instead of the whole baby! Turns out, no. You can’t. Also, the hornless cows were a major screw up (MIT Review in 2019). And, it turns out that when scientific proof is required for CRISPR claims in drug development (not in liability- and regulation-free vaccines) it resolutely fails!

[biopractify]

Can We Clone a Dinosaur? The Science Behind Jurassic Park

Ever since Jurassic Park hit the big screen, the idea of bringing dinosaurs back to life has fascinated scientists and movie lovers alike. But is it actually possible to clone a dinosaur, or is it just Hollywood magic? In this article, we’ll dive into the real science behind cloning and whether dinosaurs could ever walk the Earth again.

Can We Clone a Dinosaur? The Science Behind Jurassic Park

Ever since Jurassic Park hit the big screen, the idea of bringing dinosaurs back to life has fascinated scientists and movie lovers alike. But is it actually possible to clone a dinosaur, or is it just Hollywood magic? In this article, we’ll dive into the real science behind cloning and whether dinosaurs could ever walk the Earth again.

The Science of Cloning: A Quick Breakdown

Cloning is the process of creating a genetically identical copy of an organism. Scientists have successfully cloned animals like sheep (Dolly the Sheep), cats, and even horses using somatic cell nuclear transfer (SCNT). This technique involves taking DNA from a donor cell and inserting it into an egg cell that has had its nucleus removed. The cell is then stimulated to grow into an embryo, which is implanted into a surrogate mother.

While this method works for recently living animals, cloning a dinosaur presents major challenges.

Why Cloning Dinosaurs Is (Currently) Impossible

1. DNA Degradation Over Time

DNA is a fragile molecule that breaks down over time. Fossilized dinosaur bones are millions of years old, and even in the best conditions, DNA cannot survive for more than about 6.8 million years. Since dinosaurs went extinct around 66 million years ago, their DNA is far too degraded to be used for cloning.

2. No Complete Dinosaur Genome

Even if we found fragments of dinosaur DNA, we would need a complete genome to successfully clone one. Without a full set of instructions, we can’t recreate a living, breathing dinosaur. Unlike in Jurassic Park, where scientists filled in the gaps with frog DNA, real-life genetic engineering doesn’t work that way.

3. Finding a Suitable Surrogate

In Jurassic Park, dinosaurs were grown inside modified ostrich eggs. However, even their closest living relatives — birds — have reproductive systems that are vastly different from ancient dinosaurs. A dinosaur embryo might not be compatible with any modern-day egg, making implantation and development impossible.

Alternative Ways to Bring Dinosaurs Back

While cloning is off the table, scientists are exploring other ways to bring back dinosaurs — or at least something similar.

1. Reverse Engineering Birds

Birds are the closest living relatives of dinosaurs, and some scientists are experimenting with “de-evolving” them by manipulating their DNA. Researchers have successfully created chicken embryos with dinosaur-like traits, such as teeth and long tails, by activating ancient genes. While this won’t bring back a T. rex, it could give us a glimpse into the past.

2. Finding Preserved Cells in Amber

In Jurassic Park, scientists extract dinosaur DNA from mosquitoes trapped in amber. While this is a thrilling concept, no scientifically verified dinosaur DNA has ever been found in amber. Even if it were, it would likely be too damaged to be useful.

3. Creating a Hybrid Species

Some scientists propose using CRISPR gene-editing technology to modify existing animals, such as crocodiles or birds, to resemble dinosaurs. While this wouldn’t be a “real” dinosaur, it could lead to the creation of dinosaur-like creatures with certain genetic traits.

Could Jurassic Park Ever Happen?

For now, cloning a dinosaur is scientifically impossible due to DNA degradation and missing genetic information. However, advancements in genetic engineering may allow scientists to create dinosaur-inspired creatures in the future.

Even if we could bring dinosaurs back, should we?

Ethical concerns about de-extinction include habitat loss, ecological disruption, and the potential dangers of releasing ancient predators into the modern world.

Final Thoughts

While Jurassic Park remains science fiction, the idea of reviving prehistoric creatures continues to inspire scientific research. Whether through reverse engineering birds, hybrid experiments, or further DNA discoveries, the dream of bringing dinosaurs back may not be completely extinct.

Would you want to see a real-life Jurassic Park? Let us know in the comments!

[market-trends-bykr]

US and Japan Biotech Investment Propels Electroporation Demand

The Electroporation Instruments and Consumables Market is witnessing robust growth, driven by increasing applications in gene therapy, DNA and mRNA vaccine delivery, and precision biotechnology research. Electroporation technology enables controlled delivery of nucleic acids, drugs, and proteins into cells, making it an essential tool in both academic and clinical settings.

To Get Free Sample Report: https://www.datamintelligence.com/download-sample/electroporation-instruments-and-consumables-market

Market Size & Future Outlook

Valued at approximately USD 212.5 million in 2020, the electroporation instruments and consumables market is projected to reach around USD 350.8 million by 2028, growing at a compound annual growth rate (CAGR) of 6.8%. North America currently dominates the market with an estimated 38–40% global share, thanks to its mature biotechnology sector, strong clinical pipeline, and supportive research funding. Meanwhile, Asia-Pacific is forecasted to be the fastest-growing region, with rising investments in biotechnology and growing demand for genetic engineering solutions.

Key Market Drivers

1. Expansion in Gene Therapy and Vaccine Research Electroporation has become an indispensable method for DNA and RNA vaccine delivery. Its use enhances transfection efficiency and enables more consistent immune responses. The COVID-19 pandemic significantly accelerated its adoption in vaccine research and delivery technologies.

2. Adoption in Monoclonal Antibody Production The growing burden of autoimmune diseases, cancer, and viral infections has driven demand for monoclonal antibodies. Electroporation plays a critical role in antibody development and high-throughput screening.

3. Integration with CRISPR and Gene Editing Tools CRISPR-Cas9 and other gene-editing technologies rely on precise cellular delivery systems. Electroporation instruments provide the control needed to introduce gene editors into both somatic and stem cells.

4. Growth in Biotech Research Funding Increased government and private funding in genomic research, cell therapy, and bioengineering is bolstering demand for both instruments and consumables used in electroporation workflows.

5. Automation and Scalability Integration with automated platforms and high-throughput systems has made electroporation scalable and reproducible. Innovations in electroporator designs are expanding their usability in both small labs and large biopharma companies.

Segment Insights

Instruments Electroporation instruments, including systems designed for microbial, plant, and mammalian cells, are the backbone of the market. These devices enable precise pulse control, ensuring high efficiency and cell viability.

Consumables Consumables like cuvettes, electrodes, buffers, and electroporation plates represent over 55% of the market share. Their recurring nature makes them vital for daily lab operations. As labs scale experiments or move to GMP-compliant environments, the demand for high-quality consumables increases.

Regional Analysis

United States The US continues to dominate the market, driven by clinical trials, therapeutic development, and robust R&D activities. Companies such as Thermo Fisher Scientific, MaxCyte, and Bio-Rad Laboratories are leading product innovation. The US biotech ecosystem encourages the use of advanced electroporation systems, especially in cancer research, CAR-T cell therapy, and next-gen vaccine platforms.

Japan Japan’s market is growing steadily, supported by national strategies focused on regenerative medicine and aging-related therapies. The country's focus on precision medicine and investments in gene-editing technologies position it as a strong contributor in the Asia-Pacific electroporation segment. Japanese manufacturers are also developing compact, high-efficiency systems suited to domestic and regional research institutions.

Emerging Trends and Innovation

Pulsed-Field Electroporation Systems These systems offer controlled energy delivery and are especially useful for transfecting hard-to-reach cell types, such as neurons and stem cells.

Microprocessor-Controlled Devices Offering programmable settings, these devices deliver precision for different cell types and experiment protocols, gaining wide usage in laboratories globally.

Nanotechnology in Electroporation Integration of nanocarriers with electroporation enhances delivery specificity and reduces off-target effects.

Reagent and Buffer Advancements Next-gen electroporation buffers now increase transfection efficiency and reduce cytotoxicity, expanding the technology’s viability in sensitive applications.

Challenges & Constraints

High Cost of Equipment Electroporation devices and their consumables can be cost-prohibitive for small labs, especially in emerging economies.

Technical Expertise Requirement Proper setup and calibration are critical for successful use, necessitating skilled operators and standardized training.

Competing Technologies Other transfection techniques, including viral vectors, lipofection, and microinjection, remain strong competitors in gene and protein delivery.

Regulatory Hurdles Medical applications require strict regulatory compliance, especially in clinical-grade gene therapies, which can delay product approvals.

Competitive Landscape

The competitive space is shaped by both global leaders and emerging players. Companies such as Thermo Fisher Scientific, MaxCyte, Bio-Rad Laboratories, Eppendorf, Lonza, Mirus Bio, Harvard Bioscience, Celetrix LLC, and BEX Co. Ltd are among the key innovators.

Recent product developments include:

Thermo Fisher's Xenon electroporation platform for large-volume cell therapy applications

MaxCyte’s Flow Electroporation technology for non-viral, scalable delivery in clinical pipelines

Mirus Bio’s Ingenio System, widely used for high-efficiency research-grade applications

These firms are expanding into personalized medicine, synthetic biology, and high-efficiency immunotherapy.

Subscribe for Insights: https://www.datamintelligence.com/reports-subscription

Market Outlook

As gene therapies, cell-based treatments, and vaccine innovations evolve, the electroporation instruments and consumables market will remain a key enabler of precision medicine. Analysts expect the market to cross USD 400 million within the next decade, driven by rising clinical applications and the need for scalable, safe transfection methods.

Asia-Pacific, led by Japan, China, and South Korea, is expected to post the highest growth, while North America will retain its market leadership through continuous innovation.

Final Thought

The electroporation instruments and consumables market is transitioning from a research-only tool to a clinical-scale, therapy-enabling platform. With increasing investments in biotech, breakthroughs in gene delivery, and expanding global access, the market is poised for a transformative decade.

Firms that invest in automation, consumables innovation, and user-friendly system designs will lead the next phase of growth in this high-impact domain.

[newspressx]

Europe Cell Therapy Manufacturing Market Competitive Landscape: Forecast to 2035

The Prophecy Market Insights has officially released the Cell Therapy Manufacturing Market, By Therapy Type (Allogeneic Cell Therapy and Autologous Cell Therapy), By Technology (Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, and 3D Technology), By Source (IPSC’s, Bone Marrow, Umbilical Cord, Adipose Tissue, and Neural Stem Cells), By Application (Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, and Other),and By Region (North America, Latin America, Europe, Middle East, Asia Pacific, Africa) - Trends, Analysis and Forecast till 2032 Study, a comprehensive report spanning over 130 pages. This in-depth analysis outlines the current market landscape, product scope, and long-term projections from 2025 to 2035. The study provides strategic segmentation by key regions, offering valuable insights into regional dynamics and emerging opportunities. As the market continues to evolve, the Europe Cell Therapy Manufacturing Market is experiencing accelerated growth and expanding its global presence, driven by innovation and increased demand across multiple sectors. Request PDF Sample Copy of Report:https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21Major companies profiled in Europe Cell Therapy Manufacturing Market are: Pharmicell Co. Ltd. Merck Group Thermo Fisher Scientific Inc. Lonza Group Miltenyi Biotec GmBH Takara Bio Group STEMCELL Technologies Cellular Dynamics International Becton Dickinson & Company Bio-Rad Laboratories Inc. and others   The report’s goal is to provide in-depth industry information to assist decision-makers make crucial investment decisions while also identifying potential gaps and developments in By Therapy Type - Allogeneic Cell Therapy and Autologous Cell Therapy By Technology - Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, and 3D Technology By Source - IPSC’s, Bone Marrow, Umbilical Cord, Adipose Tissue, and Neural Stem Cells By Application - Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, and Other. To accomplish this goal, the report traces the market’s history and forecasts growth by geography. It consists of technological innovation, future technologies, and technical progress in the industry. To get a clear understanding of facts and statistics, the study defines, describes, and analyses the sales volume, value, market share, competition landscape, and SWOT analysis. Have different Market Scope & Business Objectives; Enquire for customized study: https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/21  Global Europe Cell Therapy Manufacturing Market -Regional Analysis North America: United States of America (US), Canada, and Mexico. South & Central America: Argentina, Chile, Colombia, and Brazil. Middle East & Africa: Kingdom of Saudi Arabia, United Arab Emirates, Turkey, Israel, Egypt, and South Africa. Europe: the UK, France, Italy, Germany, Spain, Nordics, BALTIC Countries, Russia, Austria, and the Rest of Europe. Asia: India, China, Japan, South Korea, Taiwan, Southeast Asia (Singapore, Thailand, Malaysia, Indonesia, Philippines & Vietnam, etc.) & Rest Oceania: Australia & New Zealand   Get 30% Discount on Europe Cell Therapy Manufacturing Market Report  https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21 Europe Cell Therapy Manufacturing Market Research Objectives: Focuses on the key manufacturers, to define, pronounce and examine the value, sales volume, market share, market competition landscape, SWOT analysis, and development plans in the next few years. To share comprehensive information about the key factors influencing the growth of the market (opportunities, drivers, growth potential, industry-specific challenges and risks). To analyze the with

respect to individual future prospects, growth trends and their involvement to the total market. To analyze reasonable developments such as agreements, expansions new product launches, and acquisitions in the market. To deliberately profile the key players and systematically examine their growth strategies.   FIVE FORCES & PESTLE ANALYSIS: Five forces analysis-the threat of new entrants, the threat of substitutes, the threat of competition, and the bargaining power of suppliers and buyers-are carried out to better understand market circumstances. Political (Political policy and stability as well as trade, fiscal, and taxation policies) Economical (Interest rates, employment or unemployment rates, raw material costs, and foreign exchange rates) Social (Changing family demographics, education levels, cultural trends, attitude changes, and changes in lifestyles) Technological (Changes in digital or mobile technology, automation, research, and development) Legal (Employment legislation, consumer law, health, and safety, international as well as trade regulation and restrictions) Environmental (Climate, recycling procedures, carbon footprint, waste disposal, and sustainability)   Get customized reporthttps://www.prophecymarketinsights.com/market_insight/Insight/request-customization/21 Points Covered in Table of Content of Global Personal Care Services Market: Chapter 01 - Personal Care Services Executive Summary Chapter 02 - Market Overview Chapter 03 - Key Success Factors Chapter 04 - Global Europe Cell Therapy Manufacturing Market - Pricing Analysis Chapter 05 - Global Europe Cell Therapy Manufacturing Market Background or History Chapter 06 - Global Europe Cell Therapy Manufacturing Market Segmentation (e.g. Type, Application) Chapter 07 - Key and Emerging Countries Analysis Worldwide Personal Care Services Market Chapter 08 - Global Europe Cell Therapy Manufacturing Market Structure & worth Analysis Chapter 09 - Global Europe Cell Therapy Manufacturing Market Competitive Analysis & Challenges Chapter 10 - Assumptions and Acronyms Chapter 11 - Europe Cell Therapy Manufacturing Market Research Method Personal Care Services Thank you for reading this post. You may also obtain report versions by area, such as North America, LATAM, Europe, Japan, Australia, or Southeast Asia, or by chapter. Author: Authored by Shweta.R,  Business Development Specialist at Prophecy Market Insights. This comprehensive analysis is grounded in an extensive blend of primary interviews, industry expert consultations, and in-depth secondary research. It provides strategic insights into the evolving dynamics, competitive landscape, and emerging opportunities within the global Europe Cell Therapy Manufacturing Market.   About Us: Prophecy Market Insights is a leading provider of market research services, offering insightful and actionable reports to clients across various industries. With a team of experienced analysts and researchers, Prophecy Market Insights provides accurate and reliable market intelligence, helping businesses make informed decisions and stay ahead of the competition. The company's research reports cover a wide range of topics, including industry trends, market size, growth opportunities, competitive landscape, and more. Prophecy Market Insights is committed to delivering high-quality research services that help clients achieve their strategic goals and objectives.  Contact: Prophecy Market Insights US toll free: +1 689 305 3270 Rest of world: + 91 7775049802 Email: sales@prophecymarketinsights.com We're here to deliver insights that drive decisions.

[walkingghotst]

Europe Cell Therapy Market Analysis by Business Methodologies, Financial Overview and Growth Prospects Predicted (2019-2027)

The Europe Cell therapy market is expected to reach US$ 3,610.7 million by 2027 from US$ 2,125.7 million in 2019; it is anticipated to grow at a CAGR of 6.9% during 2019–2027. 

Europe Cell Therapy Market Introduction

Cell therapy is a groundbreaking medical procedure where healthy, live cells are introduced into a patient's body to restore lost function or repair damaged tissues. This advanced field heavily relies on stem cells due to their remarkable capacity to differentiate into various specialized cells required for tissue regeneration. Moreover, cell therapy is a cornerstone in the advancement of regenerative medicines. The market is anticipated to expand considerably, fueled by the escalating prevalence of chronic diseases, the increasing embrace of regenerative therapies, and a growing stream of approvals for cell-based treatments.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/TIPRE00019052

Europe Cell Therapy Market Dynamics

The Europe Cell Therapy market is set for substantial growth, with expectations to reach US$ 3,610.7 million by 2027, up from US$ 2,125.7 million in 2019, exhibiting a CAGR of 6.9%. This expansion is primarily driven by the increasing burden of chronic diseases, the broader adoption of regenerative medicines, and a surge in the approval of cell-based therapies. Conversely, the market's progress could be impacted by the substantial cost associated with cell therapy manufacturing, especially in developing nations.

The COVID-19 pandemic created significant disruptions across Europe. At the onset, the cell therapy instrument market experienced a slump due to supply chain interruptions and diminished demand caused by widespread lockdowns. However, the demand for cell therapy saw a drastic increase, significantly bolstered by supportive government initiatives.

EUROPE CELL THERAPY MARKET SEGMENTATION

Europe Cell Therapy Market: By Therapy Type

Allogeneic

Autologous

Europe Cell Therapy Market: By Product

Consumables

Equipment

Systems and Software

Europe Cell Therapy Market: By Technology

Viral Vector Technology

Genome Editing Technology

Somatic Cell Technology

Cell Immortalization Technology

Cell Plasticity Technology

Three-Dimensional Technology

Europe Cell Therapy Market: By Application

Oncology

Cardiovascular

Orthopedic

Wound Management

Other Applications

Europe Cell Therapy Market: By End User

Research Institutes

Hospitals

Others

Europe Cell Therapy Market: By Country

Germany

France

Italy

UK

Spain

Europe Cell Therapy Market: Company Profiles

Vericel Corporation

MEDIPOST

NuVasive, Inc.

Mesoblast Limited

Smith & Nephew

Bristol-Myers Squibb Company

Cells for Cells

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

[hanltrcy]

Bioengineering Darah Universal untuk Kedaulatan, Harga diri dan Ketahanan Medis Nasional di mata internasional

Tujuan:

Membangun sistem produksi darah universal hasil rekayasa genetik dari sel punca, untuk:

Ngelawan kelangkaan donor

Mengurangi ketergantungan darah donor biologis (yang mahal dan terbatas)

Cegah reaksi imunologis lewat teknologi antigen-null

1. Grand Design – Dari Lab ke Produksi Skala Kecil

A. Sumber Sel Punca (Stem Cells)

iPSC (Induced Pluripotent Stem Cells) dari jaringan dewasa (kulit, urin, dll)

HSC (Hematopoietic Stem Cells) dari donor sumsum tulang atau darah tali pusat

Fokus: Pilih jenis sel dengan proliferasi tinggi dan stabil

B. Pengeditan Genetik: "Antigen Knockout"

Gunakan CRISPR-Cas9 buat:

Ngehapus gen antigen Rh (dan ABO target)

Opsional: knock-in penanda fluoresen untuk tracking

Tujuan: Ciptain RBC (sel darah merah) universal tanpa antigen pemicu reaksi imun

C. Kultur Diferensiasi

Inkubasi sel punca → diferensiasi terarah jadi eritrosit (RBC)

Media kultur khusus + growth factor: EPO, SCF, IL-3, dll

Inkubator otomatis, steril, dengan kontrol suhu, CO₂, O₂, pH

D. Kloning Genetik & Seleksi

Sel hasil edit dikloning buat dapetin populasi identik (kualitas stabil)

Seleksi berdasarkan:

Viabilitas

Kapasitas oksigen-binding (Hb)

Ketahanan sel terhadap lisis

Simpan batch terbaik buat produksi massal

Kalau ini berhasil, bisa punya hak kekayaan intelektual atas salah satu teknologi medis paling kritikal dunia. Dan itu bukan cuma mimpi.

mari kita tambahin satu sub-bab :

Tambahan Modul 2 – Sub-Bab: Teknologi Bio-Kloning untuk Replikasi Genetik Massal

A. Tujuan Utama Bio-Kloning

1. Gen Stability: Hindari mutasi acak di proses kultur jangka panjang.

2. Homogenitas Populasi Sel: Biar semua RBC yang dihasilkan identik kualitas dan profil genetiknya.

3. Efisiensi Produksi: Mempercepat proses replikasi sel darah yang sudah diedit genetiknya jadi universal.

B. Metodologi Bio-Kloning

1. SCNT (Somatic Cell Nuclear Transfer)

Transfer inti sel darah hasil editing (RBC precursor) ke dalam oosit kosong.

Lalu dikultur jadi blastokista, dan diambil lagi sel punca hematopoietik-nya buat diferensiasi RBC.

2. Single Cell Expansion via Cloning Chamber

Isolasi satu sel RBC precursor terbaik → dikultur dalam chamber mikrofluidik.

Diperbanyak tanpa kehilangan karakteristik genetik.

3. Microbial Vector Cloning (Opsional, untuk Gen)

Duplikasi gen hasil edit CRISPR (Rh- dan ABO-null) dalam plasmid E. coli

Gunakan sebagai template insert ke sel punca baru.

C. Integrasi ke Sistem Produksi

Setiap batch darah universal hasil kultur → wajib dari clonal lineage

Dilabeli QR-code/ID genetik buat tracking & validasi

Dilakukan whole genome sequencing sampling secara berkala

D. Manfaat Jangka Panjang

Bisa bikin gen bank darah universal

Replikasi tak terbatas dari sel master berkualitas tinggi

Bisa disesuaikan buat terapi genetik lainnya (bukan cuma darah)

[michaelgabrill]

Targeted Genome Editor Delivery Challenge

Gene editing holds the promise to treat genetic diseases at the source by correcting the faulty genetic patterns within our cells. The National Institutes of Health (NIH) has launched the TARGETED (Targeted Genome Editor Delivery) Challenge to advance genome editing technology by sourcing innovative solutions for delivering genome editors to somatic cells. The Challenge is […] from NASA https://ift.tt/lqHPxu0

[lutforrahaman]

Biotech Breakthroughs in 2022

A flurry of innovations pushed biotech ahead in 2022, with the promise of even more paradigm-shifting advancements in the years to come. From genome editing to 3-D bioprinting, a few major breakthroughs that are worth keeping an eye on include:

CRISPR-Cas9 Gene Editing CRISPR-Cas9 is a group of technologies that allow scientists to change DNA in living cells and organisms. Researchers use these systems to study genetic pathways that lead to disease and to treat genetic disorders.

The ability tech ogle to edit genes has many potential applications, from creating more nutritious crops and pharmaceuticals to advancing artificial intelligence. Scientists can now alter the DNA of microbes, plants, animals, and humans with unprecedented ease and precision.

However, the ease and precision with which these systems can be used may also raise concerns about how they are being manipulated for purposes other than treating disease. This is a key issue that will shape the future of genome editing technology and its societal impact.

Cell-Free Protein Synthesis A team of Australian National University scientists has developed a way to efficiently produce the proteins used in biological transcription and translation processes without using living cells. This advance, known as encapsulated cell-like structures (eCells), is a significant step towards developing a cost-effective and efficient platform for producing proteins that could be used in a wide range of commercially relevant applications.

Genome Editing The most well-known of these biotech innovations, genome editing allows scientists to add, remove, or alter a section of DNA in a living cell or organism. Using this technology, researchers can treat diseases caused by mutations in specific genes or create organisms that are resistant to particular pathogens. Researchers can use genome editing in somatic cells (non-germline), which are not used for reproduction, or germline cells (used to reproduce).

Bioprinting In another major biotech innovation, a team at the Stanford Biodesign Institute has developed a method to produce human tissues that can technology news be printed into 3D shapes. This new biotechnology can be used to make replacement parts for the heart, lungs, liver, and more. This advance is an important step toward developing a more reliable source of transplantable organs, which can be more easily tested for infections and other problems.

Big Data In the field of biotechnology, big data can help improve clinical trial recruitment, enable more accurate testing for infectious diseases, and accelerate drug discovery. One area that is particularly ripe for the growth of this technology is genomics, which can help identify new targets for therapies. However, the vast amount of information generated can be overwhelming, making it difficult to manage and analyze. In this regard, companies are deploying artificial intelligence and other tools to help unlock the potential of big data.

While most Americans are optimistic about the overall impact of these innovations, some are concerned about potential ethical issues that may arise from their use. Nearly seven-in-ten say that if gene editing techniques become widely available, some people would definitely or probably go too far in eliminating natural differences between individuals.

[there-i-changed-it]

Hey! Now I can bring up something relevant!

There’s a chapter in Christopher J Preston’s book The Synthetic Age (2018) on this sort of thing and how if they succeed in their goal they’ll create orphaned mutants with no place in the world (for example, he brings up the question of what animals would constitute a resurrected Wooly Mammoth’s herd, and who would teach it to forage in its natural habitat, since modern elephants don’t live in cold climates) but also most of the time the animals they try and “resurrect” are aborted failures or die in horrible ways immediately after birth due to congenital defects (page 95, he details that “an ‘extinct’ Pyrenean Ibex was born using [somatic cell nuclear transfer] to a goat mother in 2003. Unfortunately, the resurrected ibex survived only ten minutes outside the womb because of the presence of major defects in its lungs”). This is all super ethically messy (restoring habitats and ecosystems vs animal suffering vs human control over nature vs which species should you be trying to save?), and while I won’t get super deep into it, when you see these headlines you should always ask “why?”. These companies are interested in exploring restoration and “resurrection” (whether that means genomic chimeras, ‘editing’ existing genomes, or the aforementioned somatic cell nuclear transfer with a whole genome), but they are also driven by grant money and consumer engagement. Obv Colossal has picked their bet: make things people think are cool and maybe that will bring in money. They’ll slam through to get any results, consequences be damned, if it means they turn a profit. As the poster above says, these guys were suspicious from the start because of the wooly mammoth mouse (they got the gene to work, which was cool, but the headlines were wack). However, hype carries things away, and it’s always worth looking into something like this a little deeper to see what has actually been done.

To anyone who follows me, I don't care about nor trust Colossal Biosciences anymore (The people behind the "Wooly Mice"). They have proven themselves to be headline-chasing grifters after this latest stunt. They are claiming to have de-extincted *Aenocyon dirus*, aka the Dire Wolf, by editing just 20 genes from the the DNA of a Grey Wolf (*Canis lupus*) to make this thing:

If it wasn't clear from their scientific names, Grey Wolves and Dire Wolves aren't remotely related to one another aside from being Canids, despite what pop culture like Game of Thrones would have you believe. If they did look like each other, it would have had to be via convergent evolution, as they only shared a common ancestor over 5 million years ago.

This distinction, however, isn't found in the publicized articles about this so-called resurrected Dire Wolf and makes their claim that they brought the Dire Wolf back by simply editing *20* genes from the genome of a Grey Wolf laughable. A Dire Wolf would have shared more in common genetically with a Maned Wolf (*Chrysocyon brachyurus*) or Bush Dog (*Speothos venaticus*) than it would with a Grey Wolf.

Bottom line, don't fall for whatever this company is trying to tell you. If the Dire Wolf were to be brought back, it wouldn't be via something like this, and certainly wouldn't *look* like this. If you want an idea as to how a real Dire Wolf would look like in life, here is some fantastic paleoart by artist Mauricio Antón:

Addendum: I seem to have partially miscalculated Dire Wolf genetics. They were not closer to Maned Wolves or Bush Dogs, but they were still not closely related to Grey Wolves. They were basal members of Canini, related to canids like Jackals (genus Lupulella) but distinct from them. I am sorry for this misinformation in my attempt to correct other misinformation. My main point, however, is still correct.

[mednerds]

Panel Lays Out Guidelines for CRISPR-Edited Human Embryos

By Lisa Winter (The-Scientist). Image: © ISTOCK.COM, POSTERIORI

On September 3, 2020, the International Commission on the Clinical Use of Human Germline Genome Editing released a report that reviews the available research and determines gene editing’s ethical use on human embryos. The 225-page document offers a roadmap to the testing and regulations necessary to develop the technology and ultimately concludes that the technology is not yet reliable enough to use on humans. Any country that permits its scientists to do so in the future should limit the activity to severe single-gene diseases.

The commission, composed of dozens of scientists worldwide, was formed after Chinese geneticist He Jiankui claimed in 2018 to have used CRISPR-Cas9 on a set of twins and a third baby to make them HIV-resistant. While the validity of the editing has yet to be determined, He’s claims have been met with international condemnation and a three-year prison sentence for illegally practicing medicine.

Somatic gene editing introduces altered DNA into some of the body’s cells post-development as a means to treat genetic conditions. Germline editing manipulates DNA in the earliest stages of embryonic development, affects all tissue types, and permits the organism to then pass down those alterations to their offspring. Instead of treating the disease, germline editing would theoretically be able to eliminate it not only from the organism but from its lineage completely, making it attractive in the context of heritable genetic diseases.

Although manipulating genomes via CRISPR has become commonplace in genetic labs around the world, the commission states that, currently, “the outcomes of genome editing in human zygotes cannot be adequately controlled” and could bear unintended consequences.

“It underscores what really I think most researchers who think about this are aware of: There must not be any use of germline editing for clinical purposes at this time,” Jennifer Doudna, a geneticist at the University of California, Berkeley, who was not a member of the commission, tells STAT. “And the reason is the technology is just too early-stage and we don’t understand well enough how it works in human embryos.”

Once it is possible to safely make these changes, the commission advises, countries could adopt policies allowing this technology only for the cases when a single gene is responsible for the disorder, such as sickle cell anemia, cystic fibrosis, or Tay-Sachs.

“We think the bar should be high, and appropriately so,” Richard Lifton, cochair of the panel, tells The Guardian. “If you are going to be creating human beings, you want to know that you can reliably make the edits you’re intending. If you can’t do it reliably, without introducing unintended effects, you shouldn’t be going [forward].”

[donnnoir]

Tears before their time...

(originally posted from Austin, Texas on June 16, 2019; I have edited the original to make it more readable and relevant.  The original showed obvious signs of the stress I was under at the time.  Causing me to appear “mad” shall we say.  Rather than completely re-write the piece I elected to do some deep revision and editing.  I note this as an attempt at maintaining continuity and context; should anyone have read my previous posting.  G-dspeed to thee and all of us…)

Bit by bit, I will find the means to accomplish this damnable project, my blog.  Though in all Honesty, I fear it is too little too late.  I should have been disseminating much of this information twenty plus years ago, to as wide a segment of the population as possible.   Nonetheless by the smallest of degrees the Good Lord will yet work a miracle.  But for ten righteous souls the cities of Sodom and Gomorrah would have been spared their fate.  Knowing what is to come, the pain, loss, horrors and catastrophes; over the years I have spent many nights when alone shedding tears for those I must leave behind and those whose suffering I must witness.  In the future I will not have the luxury of mourning the dead.  The Living will require every ounce of my energy and focus.  Their minds and souls will be stripped bare, constantly in a state of disbelief and overwhelmed by shock.  Left to their own, most would be in a perpetual state of shock losing all focus eventually laying down to die.  To overcome this; their minds must hear a booming series of commands, giving them purpose, focus and a direction to move.  Initially their movements will be slow and jerky constantly trying to remember what they are suppose to be doing.  This is because each of us is a composite being; constructed of a spirit, body and mind.  This composite as a whole constitutes a “soul”!  Each of the three elements is interdependent upon each other.  Our “minds” are both the most powerful and most fragile of the three.  As a consequence, when the mind becomes overloaded by any situation or circumstance, from sleep deprivation, hunger, exigent emotions and or trauma.  The quickest and at times best way to get it back to functioning properly or “rebooting” is to have one of the other two elements of our “soul” demand over-riding access to our mental operations.  For “us” fellow humans, this is usually best accomplished via requiring the overwhelmed individual to do some physical operation/action that is rote to them.  As the body’s somatic memory kicks in, it increasingly requires over-riding control of the mind thereby pushing it to function “normally”.  The military conditions a similar response into recruits.  Under stress the recruits learn to perform certain actions that their Drill Instructors bark at them.  The reasons are so that when the recruits get trapped or logger headed under fire and their minds are overwhelmed, a voice booms familiar commands.  Their bodies know the prescribed action and they do it despite the sensation they are going to be killed doing so.  Yes some are, but if they remain non-responsive they will all be killed in short order.  Thus for my part, I must always be certain and unaffected by the horrors of the deaths of family and friends.  When the living look into my eyes all that they must see is my certainty and resolve.  With the ultimate knowledge that should they waste my time and what resources the group may possess, I will callously leave them behind with less effort than I spent sending my friends or family to die, even leaving their bodies where they lay.  I must appear as heartless and cruel as the enemies we will be fighting.  It is a war that we, mankind must win!  Knowing this; having already seen and felt the loss I, we must endure.  My only recourse on nights as circumstance occasioned I should be alone was to feel and live through the loss, even for those yet unborn that will die before their time.  I swore I would never waste nor thoughtlessly shed their precious blood; instead like a miser hoarding his wealth, every iota spent must bring the most benefit to everyone, and our cause.  Always knowing that in due course even my blood will be required.  Sadly the most damaging engagements, actions and effects will come form our own, our fellow human beings.  Those that have over the years facilitated the agendas of their demonic overlords, that they now prefer to call aliens. These True Believers think in part or en mass they will escape because of the benefits afforded them by the technologies they have acquired.  That these will grant unto them the necessary advantages to go out into the Cosmos, our Multi-verse to be their own gods.  Via alteration of their genome they believe they will become something superior to being Human.  This philosophy is currently known as Trans-Humanism; it was popularly known as Eugenics during WWII.  A common and well known goal of the Nazi’s and their Human Experimentation in their death camps.  After a couple of face-lifts and attachment of a more scientific and progressive sounding name we the fourth reich have Trans-Humanism.  Because make no excuses we have wrought a fourth reich.  This courtesy in part by operation paperclip and a delusionally paranoid “military industrial complex”.  It is worse than anything mankind has presumed in epochs past.

In the here and now, I continue to be targeted by soft kill technologies that are deployed throughout the country under the guise of crowd control.  This is in conjunction to my being FOXed by elements of the Shadow Government.  This protocol includes the placing of various chemical compounds, some radioactive and poisonous substances into what I ingest, the clothes I wear and at times even aerosol applications.  Several times they gassed me with some kind of an anesthetic, presumably to dull my senses making me more compliant and or suggestible.  All required varying degrees of mental acuity and other energies to remain rationale and cognitive of my surroundings. Only by the Grace of the Divine am I still alive.  I am exhausted, but I will not lose nor capitulate.  Yeeppie all kinds of fun

[lesbianrustcohle]

I won't argue with most of this, but I actually just gave a final presentation two days ago on de-extinction for my class on natural history museums. I interviewed someone who actually works on a team that's making good progress in trying to bring back mammoths – in March of this year (2024), they created the first Asian elephant stem cells from somatic cells, which is a huge step in both mammoth de-extinction and elephant conservation. I think there are some misconceptions about mammoths and mammoth de-extinction here.

First of all, the current leading group that's working on mammoth de-extinction is a for-profit company. They're not taking money away from conservation nonprofits, they're taking rich investor money away from mediocre tech startups, and actually, they do funnel quite a bit of that money back into conservation efforts. My strong impression is that most de-extinction researchers are conservationists who are so distressed by extinction that they want to undo it. (The same company is also working on thylacine and dodo de-extinction.)

Asian elephants and mammoths share 99.6% of their genome. Asian elephants and woolly mammoths are actually more closely related to each other than either one is to African elephants. Let that sink in. Mammoths were essentially hairy elephants. Proportionally speaking, you simply don't have to edit very much of the Asian elephant genome with CRISPR to get a mammoth.

Researchers don't have the time and money to perfectly replicate the mammoth genome by editing the Asian elephant genome, but they can get close. They can create hybrids that look like mammoths and act in the ways we know mammoths acted – very similar to living elephants – and until they have enough of them to form social groups, those individuals will probably be perfectly happy to hang out with elephants!

Mammoth habitat does still exist. They ranged in warmer places than we commonly think they do, and a recent estimate puts Earth's current carrying capacity for mammoths at 50,000 individuals. We have places to put them where they could be happy, and rewilding those places along with other species like bison could create even more of that biome.

And since we're talking about bison – which, yes, should absolutely be rewilded! it's not a zero sum game! – almost all bison in the States today are actually domestic cattle/bison hybrids that look and act like "pure" bison. Are the Yellowstone bison not real bison? Mammoths and elephants are just about as related as bison and cattle, from what I can find. So would an artificial hybrid between those species that looks and acts like a mammoth be fake?

There was this post a while ago where somebody was saying that Cheetahs aren't well suited to Africa and would do well in Midwestern North America, and it reminded me of Paul S. Martin, the guy I'm always pissed off about.

He had some good ideas, but he is most importantly responsible for the overkill hypothesis (idea that humans caused the end-Pleistocene extinctions and that climate was minimally a factor) which led to the idea of Pleistocene rewilding.

...Basically this guy thought we should introduce lions, cheetahs, camels, and other animals to North America to "rewild" the landscape to what it was like pre-human habitation, and was a major advocate for re-creating mammoths.

Why am I pissed off about him? Well he denied that there were humans in North America prior to the Clovis culture, which it's pretty well established now that there were pre-Clovis inhabitants, and in general promoted the idea that the earliest inhabitants of North America exterminated the ecosystem through destructive and greedy practices...

...which has become "common knowledge" and used as evidence for anyone who wants to argue that Native Americans are "Not So Innocent, Actually" and the mass slaughter and ecosystem devastation caused by colonialism was just what humans naturally do when encountering a new environment, instead of a genocidal campaign to destroy pre-existing ways of life and brutally exploit the resources of the land.

It basically gives the impression that the exploitative and destructive relationship to land is "human nature" and normal, which erases every culture that defies this characterization, and also erases the way indigenous people are important to ecosystems, and promotes the idea of "empty" human-less ecosystems as the natural "wild" state.

And also Martin viewed the Americas' fauna as essentially impoverished, broken and incomplete, compared with Africa which has much more species of large mammals, which is glossing over the uniqueness of North American ecosystems and the uniqueness of each species, such as how important keystone species like bison and wolves are.

It's also ignoring the taxa and biomes that ARE extraordinarily diverse in North America, for example the Appalachian Mountains are one of the most biodiverse temperate forests on Earth, the Southeastern United States has the Earth's most biodiverse freshwater ecosystems, and both of these areas are also a major global hotspot for amphibian biodiversity and lichen biodiversity. Large mammals aren't automatically the most important. With South America, well...the Amazon Rainforest, the Brazilian Cerrado and the Pantanal wetlands are basically THE biodiversity hotspot of EVERYTHING excepting large mammals.

It's not HIM I have a problem with per se. It's the way his ideas have become so widely distributed in pop culture and given people a muddled and warped idea of ecology.

If people think North America was essentially a broken ecosystem missing tons of key animals 500 years ago, they won't recognize how harmful colonization was to the ecosystem or the importance of fixing the harm. Who cares if bison are a keystone species, North America won't be "fixed" until we bring back camels and cheetahs...right?

And by the way, there never were "cheetahs" in North America, Miracinonyx was a different genus and was more similar to cougars than cheetahs, and didn't have the hunting strategy of cheetahs, so putting African cheetahs in North America wouldn't "rewild" anything.

Also people think its a good idea to bring back mammoths, which is...no. First of all, it wouldn't be "bringing back mammoths," it would be genetically engineering extant elephants to express some mammoth genes that code for key traits, and second of all, the ecosystem that contained them doesn't exist anymore, and ultimately it would be really cruel to do this with an intelligent, social animal. The technology that would be used for this is much better used to "bring back" genetic diversity that has been lost from extant critically endangered species.

I think mustangs should get to stay in North America, they're already here and they are very culturally important to indigenous groups. And I think it's pretty rad that Scimitar-horned Oryx were brought back in their native habitat only because there was a population of them in Texas. But we desperately, DESPERATELY need to re-wild bison, wolves, elk, and cougars across most of their former range before we can think about introducing camels.

[walkingghotst]

Europe Cell Therapy Market Opportunity Assessment, Analysis, Size, Share and Key Segments (2019-2027)

The Europe Cell therapy market is expected to reach US$ 3,610.7 million by 2027 from US$ 2,125.7 million in 2019; it is anticipated to grow at a CAGR of 6.9% during 2019–2027. 

Market Introduction

Cell therapy is a medical procedure involving the introduction of live, whole cells into a patient's body via injection, implantation, or grafting. The fundamental principle of this technology is to restore function by replacing diseased cells with healthy, working ones. Stem cells are central to these advanced therapies because of their unique ability to develop into the specific cell types required to repair damaged or defective tissues. Moreover, cell therapy is integral to the advancement of regenerative medicine. The anticipated growth of the Cell therapy market during the forecast period is likely to be propelled by the increasing incidence of chronic illnesses, the growing utilization of regenerative medicine approaches, and a rising count of approved cell-based therapies.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/TIPRE00019052

Market Dynamics

Several factors are poised to stimulate the expansion of the Cell therapy market in the years ahead, including the growing prevalence of chronic diseases, the increasing acceptance of regenerative medicine, and the rising number of approvals for cell-based treatments. Conversely, a potential impediment to market growth during the forecast period is the significant expense associated with cell therapy manufacturing, particularly in emerging economies.

The COVID-19 pandemic posed a major challenge throughout the European region. The market for cell therapy instruments experienced some initial contraction at the onset of the crisis due to factors such as supply chain disruptions and decreased demand resulting from widespread lockdowns across European nations. However, subsequent government support and initiatives led to a substantial surge in the demand for cell therapy.

Market Scope

The European Cell therapy market's scope is defined by therapy type, product, technology, application, end user, and country. Considering therapy types, the allogeneic segment held the largest market share in 2019, primarily attributed to the significant number of approved products available for clinical application. Nevertheless, the autologous segment is also expected to exhibit the highest CAGR within the market throughout the forecast period.

Major Sources and Companies Listed

Several major primary and secondary sources associated with the Europe Cell therapy market report are the World Health Organization (WHO), European Centre for Disease Prevention and Control (ECDC), Alliance for Regenerative Medicine, National Institutes of Health, Anthony Nolan Foundation, among others.

EUROPE CELL THERAPY MARKET SEGMENTATION

Europe Cell Therapy Market: By Therapy Type

Allogeneic

Autologous

Europe Cell Therapy Market:  By Product

Consumables

Equipment

Systems and Software

Europe Cell Therapy Market: By Technology

Viral Vector Technology

Genome Editing Technology

Somatic Cell Technology

Cell Immortalization Technology

Cell Plasticity Technology

Three-Dimensional Technology

Europe Cell Therapy Market: By Application

Oncology

Cardiovascular

Orthopedic

Wound Management

Other Applications

Europe Cell Therapy Market: By End User

Research Institutes

Hospitals

Others

Europe Cell Therapy Market: By Country

Germany

France

Italy

UK

Spain

Europe Cell Therapy Market: Company Profiles

Vericel Corporation

MEDIPOST

NuVasive, Inc.

Mesoblast Limited

Smith & Nephew

Bristol-Myers Squibb Company

Cells for Cells

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

[researchnester0]

Cell Therapy System Market worth $1.75 billion by 2027 & Global Demand Analysis & Opportunity Outlook 2027

Cell Therapy System Market worth $1.75 billion by 2027 & Global Demand Analysis & Opportunity Outlook 2027

The Global Cell Therapy Marketis segmented by cell origin:-embryonic cells, cord blood, bone marrow, others; by therapy type:-autologous, allogeneic; by technology:-somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, three-dimensional technology; by end-user:-hospitals, clinics, ambulatory surgical centers,…

[sapanas]

Cell Therapy Market to Significant Growth Foreseen by 2017 – 2023

The global cell therapy market is due to grow at a CAGR of 10.6% during the forecast period of 2017 to 2023 according to Market Research Future's latest report on the subject. Cell therapy has emerged as a transformative field in biotechnology due to its use for the targeting of various diseases at a cellular level. The above-average growth expected by this market will primarily be due to the rapidly advancing healthcare sector and growing breakthrough research and development activities.

Cell therapy is finding a growing number of applications in healthcare and is often used in combination with gene therapy. Presently, applications of cell therapy include urinary problems, cancers, autoimmune disease, and infectious disease among several others. The growing prevalence of chronic and lifestyle diseases is an important driver for the cell therapy market. Cell therapy is also being developed in regenerative medicine which carries massive potential once it clears the research phase. Increasing geriatric population with health issues and technological advancements are some other factors governing market growth. government assistance for research and improvements being made in existing regulatory frameworks are expected to pave the way for future market opportunities.

However, it should be noted that the high cost of manufacturing at present and the lack of awareness or appropriate healthcare infrastructure are expected to challenge market growth.

Get Free Sample of This Report @ https://www.marketresearchfuture.com/sample_request/5066

Market Segmentation

The global cell therapy market is segmented on the basis of cell source, type, technology, application, end-user, and region. By type, the market is divided between autologous and allogeneic.

By technology, the market is segmented into viral vector technology, somatic cell technology, cell immortalization technology, genome editing technology, cell plasticity technology, and three-dimensional technology. The viral vector segment is sub-segmented into in-vivo gene modification of cells and ex-vivo gene modification of cells.

By cell source, the market is segmented to include bone marrow, umbilical cord blood-derived cells, adipose tissue, pluripotent stem cells (iPSCs), and neural stem cells.

By application, the market is segmented into cardiovascular, musculoskeletal, gastrointestinal, neurological, dermatology, oncology, wound & injuries, ocular, and others.

By end-user, the market is categorized into regenerative medicine centers, diagnostic centers, hospitals & clinics, research institutes and others.

The regional segmentation of the market divides it into the Americas, Europe, Asia Pacific and the Middle East & Africa.

Regional Analysis

The Americas with their inclusion of North America lead the market with the largest share due to the rising awareness regarding cell therapy in the region and the presence of an advanced healthcare sector. High healthcare expenditure, the presence of a large geriatric population and the growing demand for effective regenerative medicine are some of the important factors driving market growth. Europe accounts for the second largest regional segment due to the comparable growth pattern to that of the Americas. Moreover, the region has forward-thinking government policies which support research and development in the advancement of the healthcare sector.

The Asia Pacific accounts for the fastest growing region in the global market due to the presence of a massive patient pool and a rapidly developing healthcare sector. rising disposable incomes and urbanization in the region has increased the demand for advanced healthcare. Healthcare expenditure in the region is growing steadily and is expected to augment the cell therapy market in APAC.

Complete report is available @ https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=5066

Key Players

Prominent players in the global cell therapy market that have been included in MRFR's report are Cognate, ANTEROGEN.CO.,LTD., NuVasive, Inc., GlaxoSmithKline plc, Osiris, PHARMICELL, Pluristem, Genzyme Corporation, CELLECTIS, Advanced Tissue, Novartis AG, EUFETS GmbH, Cynata, BioNTech IMFS, JCR Pharmaceuticals Co., Ltd, Grupo Praxis, and MEDIPOST among others.

Latest Industry News

Novartis has received approval from the European commision for its CAR-T cell therapy.

After partnering with Regeneron, Bluebird is now looking out for more partnerships and collaborations to add to its capabilities as it works toward the advancement of cell therapy.